Also known as factor VIII, antihemophilic factor, and FVIII.
Phase 3b switch study shows denecimig well tolerated after direct switch from emicizumab; pen injector preferred and thrombin generation rose to normal without excess clotting.
Three researchers honoured for creating a bispecific antibody that mimics Factor VIII, enabling subcutaneous dosing and bleed prevention irrespective of inhibitors.
Interim FRONTIER4 data show consistent safety and efficacy of denecimig across weekly, biweekly and monthly dosing, with low injection-site reactions and high zero-bleed rates.
Phase‑3 FRONTIER4 interim denecimig data across ages and monthly/biweekly/weekly dosing, plus first paediatric explorer10 concizumab 32‑week results for children up to 11 with inhibitors.
